CY1109910T1 - Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων - Google Patents

Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων

Info

Publication number
CY1109910T1
CY1109910T1 CY20101100256T CY101100256T CY1109910T1 CY 1109910 T1 CY1109910 T1 CY 1109910T1 CY 20101100256 T CY20101100256 T CY 20101100256T CY 101100256 T CY101100256 T CY 101100256T CY 1109910 T1 CY1109910 T1 CY 1109910T1
Authority
CY
Cyprus
Prior art keywords
matrix
treatment
polyacrylic acid
diseases
derivative
Prior art date
Application number
CY20101100256T
Other languages
English (en)
Inventor
Luigi Bruschi Stefano De
Federico Mailland
Original Assignee
Polichem S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem S.A. filed Critical Polichem S.A.
Publication of CY1109910T1 publication Critical patent/CY1109910T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτεται μια υδρόφιλη μήτρα, η οποία περιέχει: a) τουλάχιστον ένα παράγωγο πολυακρυλικού οξέος σε προτιμώμενες ποσότητες 0.5- 40%, b) τουλάχιστον έναν αιθέρα κυτταρίνης σε προτιμώμενες ποσότητες 30-90% και c) τουλάχιστον έναν παράγοντα αποσάθρωσης σε προτιμώμενες ποσότητες 2-50%, ως προς το βάρος της μήτρας. Η μήτρα χρησιμοποιείται σε συνδυασμό με τουλάχιστον μια φαρμακευτικώς αποδεκτή δραστική ουσία για την παραγωγή στερεών βιοπροσφυομένων συνθέσεων ελεγχομένης απελευθέρωσης για την αγωγή κολπικών ασθενειών, όπως αιδιοκολπική καντιντίασης, βακτηριακή κολπίτης ή τριχομονάδοση. Η μήτρα χρησιμοποιείται σε στερεές συνθέσεις σε ποσότητες περίπου 5-60%, κατά προτίμηση 20-40%, και την δραστική ουσία σε ποσότητες περίπου 2-70%, κατά προτίμηση 5-50% ως προς το βάρος της σύνθεσης.
CY20101100256T 2006-06-29 2010-03-19 Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων CY1109910T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116269A EP1872775A1 (en) 2006-06-29 2006-06-29 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
EP07730288A EP2032123B1 (en) 2006-06-29 2007-06-21 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders

Publications (1)

Publication Number Publication Date
CY1109910T1 true CY1109910T1 (el) 2014-09-10

Family

ID=37433668

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100256T CY1109910T1 (el) 2006-06-29 2010-03-19 Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων

Country Status (25)

Country Link
US (1) US8865201B2 (el)
EP (2) EP1872775A1 (el)
JP (1) JP5205374B2 (el)
KR (1) KR101443149B1 (el)
CN (2) CN103071157A (el)
AR (1) AR061771A1 (el)
AT (1) ATE455534T1 (el)
BR (1) BRPI0713298A2 (el)
CA (1) CA2652226C (el)
CO (1) CO6140022A2 (el)
CY (1) CY1109910T1 (el)
DE (1) DE602007004486D1 (el)
DK (1) DK2032123T3 (el)
EA (1) EA018257B1 (el)
ES (1) ES2339069T3 (el)
HK (1) HK1128587A1 (el)
HR (1) HRP20100159T1 (el)
MA (1) MA30597B1 (el)
MX (1) MX2008016508A (el)
NO (1) NO20090095L (el)
PL (1) PL2032123T3 (el)
PT (1) PT2032123E (el)
RS (1) RS51279B (el)
SI (1) SI2032123T1 (el)
WO (1) WO2008000683A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
EP2163240A1 (en) * 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
JP5608167B2 (ja) * 2008-10-23 2014-10-15 ヘンケル コーポレイション 加工デンプンを含む医薬ペレット、およびそれの治療への応用
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
EP2243482A1 (en) * 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
BR112016009008B8 (pt) * 2013-10-22 2023-01-31 Therapeuticsmd Inc Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN105796520A (zh) * 2014-12-29 2016-07-27 四川滇虹医药开发有限公司 一种缓释型硝酸布康唑直压片剂及其制备方法
JP6579529B2 (ja) 2015-01-23 2019-09-25 バイオシディウム アイピー ホルコ カンパニー 抗菌組成物
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3525765A1 (en) * 2016-10-13 2019-08-21 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
CN109010320B (zh) * 2018-09-18 2021-09-14 浙江汇能生物股份有限公司 一种双释型聚卡波非钙颗粒剂及制备方法和畜禽中的应用
CN114129530A (zh) * 2021-12-08 2022-03-04 南京康川济医药科技有限公司 一种黄体酮缓释组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2232438A (en) 1934-08-04 1941-02-18 Schering Corp Unsaturated pregnanolones and pregnandiones and a method of producing the same
US2243887A (en) 1935-11-09 1941-06-03 Schering Corp Tertiary carbinols of the cyclopentano-polyhydrophenanthrene series and a method of producing the same
US2251939A (en) 1935-11-22 1941-08-12 Schering Corp Tertiary alcohols of the cyclopentano polyhydro phenanthrene series and a method of producing the same
US2379832A (en) 1936-06-02 1945-07-03 Schering Corp Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
US2265976A (en) 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
US2314185A (en) 1939-09-01 1943-03-16 Zondek Bernhard Process for the manufacture of progesterone
BE665514A (el) 1964-06-16
NL146838B (nl) 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
JP2004501190A (ja) * 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
FR2813865B1 (fr) 2000-09-08 2002-12-20 Rexam Sofab Dispositif a buse unique pour la distribution selective de deux produits
AU7384700A (en) 2000-09-19 2002-04-02 Cima Labs Inc Pharmaceutical compositions for rectal and vaginal administration
US6951654B2 (en) * 2001-03-27 2005-10-04 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
CN1302764C (zh) 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片

Also Published As

Publication number Publication date
US8865201B2 (en) 2014-10-21
RS51279B (sr) 2010-12-31
PT2032123E (pt) 2010-04-07
WO2008000683A1 (en) 2008-01-03
KR20090033341A (ko) 2009-04-02
EP2032123B1 (en) 2010-01-20
ES2339069T3 (es) 2010-05-14
KR101443149B1 (ko) 2014-09-23
MA30597B1 (fr) 2009-07-01
DK2032123T3 (da) 2010-03-08
HRP20100159T1 (hr) 2010-05-31
US20110091555A1 (en) 2011-04-21
HK1128587A1 (en) 2009-10-30
MX2008016508A (es) 2009-04-22
EP2032123A1 (en) 2009-03-11
DE602007004486D1 (de) 2010-03-11
AR061771A1 (es) 2008-09-17
CA2652226A1 (en) 2008-01-03
CN101478951A (zh) 2009-07-08
EA018257B1 (ru) 2013-06-28
NO20090095L (no) 2009-01-07
SI2032123T1 (sl) 2010-04-30
EP1872775A1 (en) 2008-01-02
EA200900087A1 (ru) 2009-06-30
JP5205374B2 (ja) 2013-06-05
PL2032123T3 (pl) 2010-06-30
JP2009541419A (ja) 2009-11-26
CO6140022A2 (es) 2010-03-19
CA2652226C (en) 2014-08-12
CN103071157A (zh) 2013-05-01
BRPI0713298A2 (pt) 2012-04-17
ATE455534T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
CY1109910T1 (el) Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων
Johnson et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir
Adams et al. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
AR070731A1 (es) Composicion farmaceutica para farmacos poco solubles
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
CO5060477A1 (es) Forma de dosificacion de nefazodona
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
ES2482190T3 (es) Uso de oligómeros de ácido láctico en el tratamiento de infecciones ginecológicas
RS53591B1 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INTERNAL HEARING DISORDERS
Major et al. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine
CO6251360A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
AU2017206199B2 (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
JP2022070924A (ja) アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
Patel et al. Development and evaluation of mucoadhesive vaginal tablet of sertaconazole for vaginal candidiasis
SV2006001916A (es) Formulaciones farmaceuticas transdermales
Jain et al. In vitro testing of rationally designed spermicides for selectively targeting human sperm in vagina to ensure safe contraception
KR20200060413A (ko) 미생물 감염의 치료 및/또는 예방에서 사용하기 위한 글루콘산 유도체
PE20231946A1 (es) Formulacion solida
HN2006023741A (es) " formulaciones de liberacion prolongada de principios activos de zolpidem hemitartrato"
Aitken et al. Bridging the gap between male and female fertility control; contraception-on-demand
NZ588470A (en) Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases
PE20220381A1 (es) Formulacion de tableta vaginal
ES2244324A1 (es) Composiciones diureticas de liberacion prolongada.